Skip to content
DataLookout
Menu

NCT07931313

PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary endpoint(s) modified, enrollment reduced 76%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 534 → 130 participants Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Phase changed: Phase 2/3 → Phase 2
    • Primary and study completion moved earlier from Feb 28, 2037 to Jun 30, 2029
    • Secondary endpoints: 6 to 3
    • Study description expanded, about 1 word
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The rate of 1-year progression-free survival
Timeframe: 12 months since randomization

Secondary (3)

The rate of 1-year overall survival
The rate of 18-months overall survival
Postoperative complications within 30 days after surgery

Arms and interventions

Primary Debulking SurgeryExperimental

Maximal-effort cytoreductive surgery will be completed within 3 weeks after pathologic diagnosis, followed by 6 cycles of first-line chemotherapy. The interval from surgery to the first postoperative chemotherapy cycle should not exceed 8 weeks unless medically necessary.

Neoadjuvant Chemotherapy Followed by Interval Debulking SurgeryActive comparator

Participants will receive 3 cycles of neoadjuvant chemotherapy, undergo interval debulking surgery with maximal-effort cytoreduction, and then receive 3 additional cycles of chemotherapy. The interval from surgery to the first postoperative chemotherapy cycle should not exceed 8 weeks unless medically necessary.

Procedures: Upfront cytoreductive surgery, Interval debulking surgery

Drugs: Platinum-based chemotherapy

Sites

2 sites in 1 country